GlassScriptPhysician profile
Merilee Jacobson
NPI 1003656018
$3,252.32
in general payments reported to CMS, 2019-2025
20 companies · $2,707 in 2025
The $2,707 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $545 · 2025: $2,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Travel and Lodging: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.65 |
| Travel and Lodging | $1,270.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,027.36 | 2024-2025 | Minimed 780g |
| Novo Nordisk INC | $224.61 | 2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $131.85 | 2025 | |
| Tandem Diabetes Care, INC. | $117.73 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $112.67 | 2024-2025 | Gvoke Hypopen |
| Pfizer INC. | $77.44 | 2025 | |
| Beta Bionics, INC. | $65.44 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lilly USA, LLC | $64.28 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $63.75 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $49.84 | 2024-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.00 | 2024-2025 | Jardiance, Synjardy |
| Rgh Enterprises LLC | $45.00 | 2025 | |
| Amgen INC. | $43.63 | 2024-2025 | Repatha, Otezla, Otezla |
| Sequel Med Tech, LLC | $36.77 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $33.75 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.55 | 2024-2025 | Breztri |
| Dexcom, INC. | $26.54 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Radius Health, INC. | $18.43 | 2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $18.31 | 2025 | |
| Merck Sharp & Dohme LLC | $16.37 | 2025 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merilee Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.